Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics (ARQT) granted an aggregate 57,000 restricted stock units (RSUs) of its common stock to 11 newly hired employees, effective September 1, 2026, as inducement awards under its 2022 Inducement Plan.

Rhea-AI Summary

Arcutis Biotherapeutics (ARQT) granted an aggregate 57,000 restricted stock units (RSUs) of its common stock to 11 newly hired employees, effective September 1, 2026, as inducement awards under its 2022 Inducement Plan.

The RSUs vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date, subject to continued employment, and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Market Context

The prior inducement-grants announcement was followed by a 2.49% 24-hour move on August 7. That comp...

Analysis

The prior inducement-grants announcement was followed by a 2.49% 24-hour move on August 7. That comparison frames the current award as recurring compensation activity; the active S-3ASR remains a relevant financing and resale-risk consideration.

Key Figures

Restricted stock units: 57,000 RSUs Recipients: 11 employees Grant date: September 1, 2026 +2 more

5 metrics

Restricted stock units 57,000 RSUs Granted to newly hired employees

Recipients 11 employees Newly hired employees receiving grants

Grant date September 1, 2026 Date of inducement grant

Vesting period 4 years RSU vesting schedule

Annual vesting 25% Vests on each annual anniversary

Historical Context

5 past events · Latest: Sep 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 02	Conference presentation	Neutral	-0.8%	Management scheduled a fireside chat at the Morgan Stanley healthcare conference.
Aug 07	Inducement grants	Neutral	+2.5%	Arcutis granted restricted stock units and options to newly hired employees.
Aug 05	Quarterly earnings	Positive	-2.5%	Arcutis reported higher revenue, net income, guidance, and operating cash flow.
Jul 16	Board appointment	Neutral	-0.1%	Christopher Peetz joined the board effective July 15, 2026.
Jul 15	Earnings scheduling	Neutral	-0.1%	Arcutis scheduled its second-quarter results and conference call for August 5.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent company news produced mixed reactions, including a 2.49% gain after prior inducement grants and a 2.47% decline after positive quarterly results.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), vesting

3 terms

restricted stock units financial

"grant of an aggregate of 57,000 restricted stock units (RSUs)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

vesting financial

"The RSUs will vest over four years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 57,000 restricted stock units (RSUs) of Arcutis common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to each employee’s continued employment with Arcutis through the applicable vesting date.

Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:

Media
Amanda Sheldon, head of Corporate Communications

media@arcutis.com

Investors
Brian Schoelkopf, head of Investor Relations

ir@arcutis.com

FAQ

What did Arcutis Biotherapeutics (ARQT) announce regarding inducement grants?

Arcutis Biotherapeutics announced the grant of an aggregate 57,000 restricted stock units (RSUs) of its common stock to 11 newly hired employees as inducement awards under its 2022 Inducement Plan, with a grant date of September 1, 2026.

How many RSUs did Arcutis (ARQT) grant and to how many new employees?

Arcutis granted a total of 57,000 RSUs of its common stock to 11 newly hired employees as material inducement awards in connection with their commencement of employment.

What is the vesting schedule for the new Arcutis (ARQT) inducement RSUs?

The RSUs will vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date, subject to each employee’s continued employment through the applicable vesting date.

Under which plan and Nasdaq rule were the Arcutis (ARQT) inducement RSUs granted?

The inducement RSUs were granted under the Arcutis Biotherapeutics 2022 Inducement Plan and are disclosed in accordance with Nasdaq Listing Rule 5635(c)(4), which covers equity inducement awards for new employees.

When is the grant date for the new Arcutis (ARQT) inducement RSUs?

The grant date for the newly issued inducement RSUs is September 1, 2026, as approved by the Compensation Committee of Arcutis’ Board of Directors.